Announcements Trials
Browse Landscape

Status

Completed 7Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 8OTHER 1

Study Type

Interventional 33Observational 9Expanded_access 1

Sponsor

Cancer Type

Genitourinary 9Sarcoma 1

Conditions

Prostatic Neoplasms 9Prostatic Neoplasms, Castration-Resistant 6Metastatic Castration-resistant Prostate Cancer 2Pain 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Fractures, Bone 1Fatigue 1Castration-resistant Prostate Cancer 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastatic Castration-resistant Prostate Cancer 1Advanced Prostate Cancer 1

Interventions

Surveys and Questionnaires 34Blood Specimen Collection 24enzalutamide 18Radiotherapy 15Docetaxel 15Biopsy 14Abiraterone Acetate 14apalutamide 13Leuprolide 13Interviews as Topic 13Observation 12Magnetic Resonance Spectroscopy 12Watchful Waiting 10radium Ra 223 dichloride 9darolutamide 9Androgen Antagonists 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Radiosurgery 7Magnetic Resonance Imaging 7Brachytherapy 7abiraterone 6Specimen Handling 6Amplified Fragment Length Polymorphism Analysis 6Triptorelin Pamoate 5Standard of Care 5Positron Emission Tomography Computed Tomography 5Gonadotropin-Releasing Hormone 5Focus Groups 5Registries 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
Observational × Prostatic Neoplasms × radium Ra 223 dichloride × Clear all
NCT04489719 2026-02-17

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

University of Washington

Recruiting
48 enrolled
Genitourinary

Prostatic Neoplasms

NCT03315260 2024-02-08

Treatment Satisfaction With Ra-223 in Japan

Bayer

Completed
85 enrolled
Genitourinary

Prostatic Neoplasms

NCT04256993 2024-01-16

PRECISE

Bayer

Completed
1,434 enrolled
Genitourinary

Prostatic Neoplasms, Fractures, Bone

NCT04681144 2023-10-26

QOLRAD

Bayer

Completed
103 enrolled
GenitourinarySarcoma

Bone Neoplasms, Prostatic Neoplasms

NCT04281147 2022-06-23

REACTIVATE

Bayer

Completed
4,301 enrolled
Genitourinary

Prostatic Neoplasms

NCT03419442 2020-10-22

Multi-academic Center Study of Xofigo Patients

Bayer

Completed
150 enrolled
Genitourinary

Prostatic Neoplasms

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02518698 2018-09-18

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Bayer

Completed
1,163 enrolled
Genitourinary

Prostatic Neoplasms

NCT02729103 2018-01-25

Treatment Patterns in Metastatic Prostate Cancer

Bayer

Completed
565 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡